Navigation Links
BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
Date:4/26/2008

to 96 weeks. Treatment response in this study is defined as HBeAg seroconversion and viral load less than 10^4 copies/mL for 24 weeks, with undetectable viral load at the end of the 24-week period.

Indication and Important Safety Information About BARACLUDE(R) (entecavir) 0.5 mg/1 mg Tablets

BARACLUDE(R) (entecavir) is a prescription medicine used for chronic infection with hepatitis B virus (HBV) in adults where the virus is multiplying and damaging the liver. BARACLUDE does not cure HBV or stop the spread of HBV to others. People should not take BARACLUDE if they are allergic to it or any of its ingredients. BARACLUDE has not been studied in children and is not recommended for anyone less than 16 years of age.

People taking BARACLUDE(R) (entecavir) should tell their healthcare provider right away if they feel very weak or tired, have unusual muscle pain, have trouble breathing, have stomach pain with nausea and vomiting, feel cold -- especially in their arms and legs, feel dizzy or lightheaded, or have a fast or irregular heartbeat, as they may be signs of a serious condition called lactic acidosis (buildup of an acid in the blood). Lactic acidosis is a medical emergency and must be treated in the hospital. Some people who have taken medicines like BARACLUDE have developed serious liver problems called hepatotoxicity. This may occur with liver enlargement (hepatomegaly) and fat in the liver (steatosis).

People should call their healthcare provider right away if they get any of the following signs of liver problems: yellowing (jaundice) of the skin or the white part of the eyes, darkening of the urine, lightening in the color of bowel movements (stools), not feeling like eating food for several days or longer, feeling sick to the stomach (nausea), or having lower stomach pain. Lactic acidosis and hepatotoxicity have happened in some people taking medicines like BARACLUDE.

For people taking BARACLUDE who have or get HIV (the virus
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Many Heart Attack Patients Dont Get Best Emergency Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... MOUNTAIN VIEW, Calif. , Feb. 26, 2015  IRIDEX ... will release its fourth quarter and full year 2014 financial ... 2015.   In conjunction with the release, the Company will ... 5:00 p.m. Eastern Time on Thursday, March 5, ... other business developments. Interested parties may access the ...
(Date:2/26/2015)... 2015 Legislation passed today by the House ... help prevent inappropriate prescriptions in Medicare Part D from ... of Medicare Act (PIMA) of 2014 , introduced by ... (R-TX) and Ranking Member Jim McDermott (D-WA), recognizes ... and implement the right policies, said the Pharmaceutical Care ...
(Date:2/26/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/2vn6hh/radiation_therapy ) has ... - Global Strategic Business Report" report to their ... markets for Radiation Therapy Equipment in US$ Million by ... and Radiation Therapy Simulator. The report provides separate comprehensive ... Japan , Europe ...
Breaking Medicine Technology:IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2PCMA Statement on the 'Protecting the Integrity of Medicare Act' 2Radiation Therapy Equipment - Global Strategic Business Report 2015-2020: Linear Accelerator, Treatment Planning Systems, and Radiation Therapy Simulator 2
... Neurobiological Technologies, Inc. (Nasdaq: NTII ) ("NTI") announced ... dividend of $0.18 per share of common stock, which will ... as of November 30, 2009. The December 9, 2009 extraordinary ... to a plan of complete liquidation and dissolution and an ...
... , , WAYNE, Pa., Nov. 20 ... its fiscal first quarter ended September 30, 2009. ... decreased approximately $234,000, or 2.7%, to $8,435,000 during the three-month ... period last fiscal year. The Company reported the decreased ...
Cached Medicine Technology:Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share 2Escalon(R) Reports First Quarter Fiscal 2010 Results 2Escalon(R) Reports First Quarter Fiscal 2010 Results 3Escalon(R) Reports First Quarter Fiscal 2010 Results 4Escalon(R) Reports First Quarter Fiscal 2010 Results 5Escalon(R) Reports First Quarter Fiscal 2010 Results 6Escalon(R) Reports First Quarter Fiscal 2010 Results 7
(Date:2/27/2015)... Rafael, CA (PRWEB) February 27, 2015 The ... provide campers with newer facilities and to make camp more ... a better location for a Contact Football Camp. The fields ... the best in the country,” states Mike de Surville, vice ... our staff is comprised of experienced coaches with the passion ...
(Date:2/27/2015)... February 27, 2015 RDI-Engineering will be ... Pi Day event on March 14, at Moreno Valley ... demonstrations on how to use engineering software and tools, ... be hosted by Moreno Valley College’s Upward Bound Math ... Center (SSC) in hopes to encourage students to seek ...
(Date:2/27/2015)... 27, 2015 Is it reasonable – and ... practices and games, and possible to do so without causing ... sports might be at high risk for concern and could ... the issues being addressed by two introductory bills, Int. ... hearing last month in New York City. More specifically, ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Many ... for people’s health. Mercola.com has introduced organic cotton ... contain toxic flame retardant chemicals. Dr. Mercola’s Healthy ... design and better materials. Organic cotton is significantly ... Mercola’s organic bedding products are made by Naturepedic ...
(Date:2/27/2015)... 2015 According to a Feb. 12, ... drug used to treat cancer by killing cancer stem cells, ... Drug Administration (FDA) for use in the treatment of mesothelioma.* ... the FDA to encourage the development of drugs for the ... about the FDA’s decision,” said Melinda Helbock, Founder of The ...
Breaking Medicine News(10 mins):Health News:US Sports Camps Football Camps Announce New Contact Football Camp Northeast Location 2Health News:RDI-Engineering Participates in STEM”U”LATE Your Mind Event to Host Educational Exhibition 2Health News:NYSATA Athletic Trainers Provide Expert Testimony at NYC Youth Concussion and Sports Safety Hearing 2Health News:NYSATA Athletic Trainers Provide Expert Testimony at NYC Youth Concussion and Sports Safety Hearing 3Health News:New Drug Receives FDA Approval as Orphan Drug for the Treatment of Mesothelioma 2Health News:New Drug Receives FDA Approval as Orphan Drug for the Treatment of Mesothelioma 3
... the deadly H5N1 strain of bird flu. Official sources, however, point ... spread of the virus is slow. , Nigeria, the ... reported any human cases, although experts warn that due to ineffective ... virus has now been reported in 14 of Nigeria's 36 states ...
... strides ahead with greater determination from obscurity to a global ... the pandemic// outpacing us, or are countries acting too slowly ... and affected another 40 million worldwide? ,In early ... the review meeting to the United Nations General Assembly's Special ...
... ITC Hotels on patisseries, Choco Fudge has been adjudged the ... ,The judges' panel consisted of eminent writers and fashion ... will take pride of place at all ITC hotels across ... ,Through the contest in Kolkata, ITC Hotels aims to ...
... the All India Institute of Medical Sciences has requested ... strict implementation of reservation// and end to 'victimisation' of ... ,Reacting to the gherao of the sub-dean of ... upon the President to exercise his moral authority and ...
... President of India wants the Government and people to ... and organ donation. In India., ,Inaugurating the blood ... Vice President asked the government and people to work in ... blood and organs must be encouraged to save precious lives, ...
... For severe COPD patients treated with budesonide added ... short acting bronchodilator, there is a reduced risk ... formoterol and/or terbutaline ,Important new data ... two pivotal Symbicort(R) studies, announced today at the ...
Cached Medicine News:Health News:AIDS: Why the pandemic outpaces us 2Health News:AIDS: Why the pandemic outpaces us 3Health News:Addition Of Budesonide To Formoterol Reduces Risk Of Mortality 2